Patents & publications

Driving innovation and advancing scientific excellence

At Bcell Design, innovation drives everything we do. Our patents showcase our commitment to advancing biotechnology and developing new therapeutic treatments. We prioritize scientific excellence, reflected in our peer-reviewed publications, and believe in the power of shared knowledge to drive progress. Our research fuels both our innovations and global understanding of monoclonal antibodies.
Company / Patents & Publications
Bcell Design IVD Monoclonal antibodies
See Reviews

Our partners

Our patents

Explore our cutting-edge patents, safeguarding innovations in human Fc monoclonal antibody design, production, and commercialization—driving the future of biotechnology.
Bcell Design IVD Monoclonal antibodies
Technology
  • Transgenic non-human mammal for producing chimeric human immunoglobulin A antibodies
  • Transgenic non-human mammal for producing chimeric human immunoglobulin G antibodies
  • Transgenic non-human mammal for producing chimeric human immunoglobulin E antibodies
Research
  • A new Non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection
  • Antibodies against Carcinoembryonic antigen for cancer therapy and diagnostic

Our publications

01
Radiolabelled polymeric IgA: from biodistribution to a new molecular imaging tool in colorectal cancer lung metastases
02
Self-Restrained B Cells Arise following Membrane IgE Expression
03
Ternary polysaccharide complexes: Colloidal drug delivery systemsstabilized in physiological media
04
A monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies
05
Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies
06
Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia
07
COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies
08
Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination
09
Evaluation of functional assays for the diagnosis of heparin induced thrombocytopenia using 5B9, a monoclonal IgG that mimics human antibodies
10
Characterization of New Monoclonal PF4-Specific Antibodies as Useful Tools for Studies on Typical and Autoimmune Heparin-Induced Thrombocytopenia

Reviews from client and partners

5.0 (4 Reviews)
Write a review
Write a review
Submit your review
1
2
3
4
5
Submit
     
Cancel

Create your own review

Bcell
Average rating:  
 0 reviews
Dr. Marta Palicio | Werfen
R&D Innovation Director
As developers and manufacturers of IVD products we need stable and reliable sources of standard materials and the technology proposed by Bcell Design perfectly fulfills these purposes. Our collaborations with Bcell Design have been very profitable and satisfactory.
BioVendor R&D
We value our great cooperation with Bcell Design. And we were lucky to find a French company, Bcell Design, which produces a unique chimeric antibody that plays a key role in our projects. We really appreciate excellent communication, high expertise and innovative ideas, as well as meeting deadlines.
Dr. Thomas Schumacher | Virion-serion
CSO
Since the start of our collaboration more than five years ago, BCell Design and its team have proven to be a strong and reliable partner for the development and production of monoclonal antibodies. The patented technology and experience of the team has enabled us to jointly develop excellent IgM antibodies for our product portfolio.
See Reviews

How can we help?

General enquiry
Request a free sample
Custom development services
Technical support